BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

HealthDay News — In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 in Circulation.

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...